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Extraskeletal myxoid chondrosarcoma (EMC) is a rare and
morphologically distinct soft tissue sarcoma. It is characterized by
multinodular architecture, with cords or clusters of chondroblast-
like cells in an abundant background of myxoid matrix [1]. Recent
molecular cytogenic studies have confirmed its distinct nature,
exhibiting a unique and characteristic chromosomal translocation,
typically t(9; 22)(q22; q12.2), resulting in the fusion of EWSR1with
NR4A3 (genes formerly termed EWS and CHN, TEC, or NOR1,
respectively) [2e4]. EMC usually arises in the deep soft tissue of
proximal extremities [5]. In the initial growth phase, EMC tumors
are typically asymptomatic. Pain and tenderness is reported in
some cases, and tumors that are located around joints may restrict
motion. Large or superficial tumors are even known to ulcerate the
skin. Although imaging characteristics are nonspecific, most EMC
tumors appear lobulated, and highly myxoid tumors show up as a
homogeneous and elevated signal on a T2-weighted magnetic* Corresponding author. Department of Orthopaedic Surgery, Okayama Univer-
sity Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences,
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localized necrosis is seen in some cases of EMC, an EMC tumor with
a large hematoma is uncommon [7].
Here we report a case of EMC in an elderly woman presenting a
substantially large hematoma. This observation lays the premise for
this rare tumor to be included in the differential diagnosis of
hematoma-like tumors. The molecular analysis of EWSR1eNR4A3
was useful in the differential diagnosis. Since the clinical presen-
tation in this case was extremely unusual, and demographic data
are an essential part of diagnosis, the present report adds new in-
formation to existing knowledge and has implications for diagnosis
of EMC in patients presenting with a huge expanding hematoma.
The patient provided an informed consent for the use of data
concerning the case for this publication.2. Case report
A 75-year-old woman presented with a 5-year history of
asymptomatic swelling on the medial side of her left knee and with
no contributing medical or family history. On physical examination,
an elastic but firm mass was palpable from the medial to the
popliteal area of her left knee (Fig. 1). Contrast-enhanced computed
tomography (CT) revealed a 15  14  13-cm soft tissue mass
without calcification or invasion into the surrounding bone (Fig. 2).
Magnetic resonance (MR) imaging demonstrated a lobulated tumor,
with high signal intensity relative to skeletal muscle on T1-
weighted images, heterogeneous intermediate-to-high signal in-
tensity on T2-weighted images, and gadolinium-diethylenetriamine
pentaacetic acid (Gd-DTPA) enhancement on tumor margin (Fig. 3).
201Thallium scintigraphy showed increased accumulation on the
tumor edges in the early phase (Fig. 4A), which was not washed out
in the delayed phase (Fig. 4B). A needle biopsy discovered a he-
matoma with no tumor cells present. Thereafter, the patient was
carefully followed up.rights reserved.
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Fig. 1. Appearance of the medial part of the knee at the first visit. (A) Anterior view. (B)
Lateral view. An elastic but firm mass was palpable from the medial to the popliteal
area of left knee.
Fig. 2. Contrast-enhanced computed tomography (CT) imaging. Axial CT image
revealed a 15  14  13-cm soft tissue mass, suggesting a homogeneous tumor
without calcification. A mild contrast was identified at the wall of the tumor (arrow).
T. Omori et al. / Journal of Orthopaedic Science xxx (2016) 1e52Since the tumor size gradually increased in the eight months
following needle biopsy, the possibility of a chronic expanding
hematoma or soft tissue tumor was considered and surgical
resection was performed. Since the intraoperative pathological
evaluation identified no malignancy in frozen specimens, marginal
resection was performed. Macroscopically, the resected specimen
revealed a grayish white component at the tumor wall (Fig. 5A).
Microscopic evaluations showed proliferating spindle-shaped cells
and oval cells with eosinophilic cytoplasm surrounded by abundant
myxoid matrix (Fig. 5B and C). Moreover RT-PCR analyses revealed
transcripts of the EWSR1eNR4A3 fusion gene, and these analyses
were confirmed by direct sequencing (Fig. 6). Therefore, we diag-
nosed this to be a case of EMC with a rare manifestation of a huge
expanding hematoma. Considering the microscopic negative mar-
gins and advanced age, the patient was followed up without any
adjuvant treatment. The postoperative course was uneventful for
three years without any signs of local recurrence or metastasis.3. Discussion
Extraskeletal myxoid chondrosarcoma is a rare tumor that ac-
counts for approximately 3% of all soft tissue sarcomas [1]. It occurs
more frequently in men than in women (at a 2:1 ratio), with 50% of
all cases occurring during the fifth or sixth decade of life [8]. Recent
cytogenetic studies have demonstrated the distinct molecularPlease cite this article in press as: Omori T, et al., A rare manifestatio
hematoma, Journal of Orthopaedic Science (2016), http://dx.doi.org/10.10nature of EMC, involving a unique and characteristic chromosomal
translocation, typically t(9; 22)(q22; q12.2), which results in the
fusion of EWSR1 with NR4A3 [9]. Panagopoulos et al. reported that
15 of 18 analyzed EMC samples had EWSR1eNR4A3 fusion tran-
scripts [10]. In our case, the detection of the transcripts of the
EWSR1eNR4A3 fusion gene determined the diagnosis of EMC.
Tateishi et al. have reported a low rate of intratumoral hemorrhage
in EMCs (1 in 19 cases), and no hematoma formation [11]. To our
knowledge, an EMC accompanied by a huge hematoma has never
been reported in scientific literature published in the English
language.
Although diagnoses of acute soft tissue hematoma are usually
relatively easy, it is often difficult to distinguish between soft tissue
tumors and chronic soft tissue hematomas [12e14], particularly
when hematomas grow despite the lack of evident trauma. In 1980,
Reid et al. used the term “chronic expanding hematomas” to
describe lesions that grew progressively for over a month after
onset [14,15]. History of trauma is an important diagnostic factor for
chronic hematomas. Accordingly, reports of chronic expanding
hematomas in lower limbs were identified in the Medline database
for the period 1980e2010, and history of traumawas reported in 12
of 28 cases [16]. When soft tissue masses with calcification are
identified using plain radiography, differential diagnoses include
myositis ossificans, hemangioma, heteroplastic chondroma, or os-
teoma, or the presence of chronic abscesses or parasitic/infective
cysts [16]. The present patient had no history of trauma and did not
show calcification in radiological images. Currently, the etiology of
chronic expanding hematoma is not well understood, although
Labadie et al. suggested that breakdown of leukocytes, hemoglobin,
platelets, and fibrin leads to inflammatory processes that damage
capsule capillaries, increase permeability of vascular walls, and
cause bleeding from dilated microvessels beneath fibrous capsules
[17]. In agreement, Nishida et al. showed that 2-[18F]fluoro-2
deoxy-D glucose is taken up by not only malignant tumor cells but
also macrophages and tissues with granulation or inflammation,
indicating limited diagnostic value of this imaging method [18].
Among soft tissue sarcomas, liposarcoma, undifferentiated/un-
classified sarcoma, leiomyosarcoma, synovial sarcoma, extra-
skeletal Ewing sarcoma, and angiosarcoma are most commonly
associated with the formation of hematomas [19e21]. Recently,
Burgert-Lon et al. and Miyazaki et al. reported the development of
angiosarcomas in chronic expanding hematomas [22,23], and
Imaizumi et al. reported six cases of malignant fibrous histiocyto-
mas, synovial sarcomas, leiomyosarcomas, and extraskeletal Ewing
sarcomas that mimicked hematomas [21]. These authors concluded
that MR imaging is more useful than CT for characterization and
distinction between sarcomas and hematomas. Specifically, he-
matoma in sarcoma lesions appear as homogeneous signal patterns
on T2-weighted images, either in entire tumors or in portions of
tumors that have constant blood supply [21]. In contrast, chronic
hematomas that are caused by trauma appear as a heterogeneous
signal patterns throughout lesions. During MR imaging, signals
from lesions generally vary with time, likely reflecting changes in
hemoglobin levels. Accordingly, high-intensity T1-enhanced sig-
nals are attributable to methemoglobin levels in hematomas.
However, phasic changes in MR imaging signatures of hematomas
can hamper distinctions frommalignant soft tissue tumors that are
identified according to clinical and radiological findings [8]. Hence,
when a soft tissue tumor cannot be ruled out, open biopsy or
intensive and meticulous follow-up should be performed, even
when the needle biopsy is negative, and subsequent surgical R0
resection should be conducted without delay.
EMC are distinguishable from other myxoid sarcomas such as
myxoid liposarcoma and myxofibrosarcoma, warranting differen-
tial diagnosis. In the present case, proliferating spindle-shaped cellsn of extraskeletal myxoid chondrosarcoma with a huge expanding
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Fig. 3. Magnetic resonance (MR) imaging. (A, B, and C) Axial view of T1-weighted image (A), T2-weighted image (B), and gadolinium-enhanced T1-weighted image (C). (D) Coronal
view of gadolinium-enhanced T1-weighted image.
Fig. 4. Thallium scintigraphy. (A and B) Early phase (A) and delayed phase (B) are shown. Thallium scintigraphy showed mild uptake on the tumor margins in both the early and
delayed phase.
T. Omori et al. / Journal of Orthopaedic Science xxx (2016) 1e5 3and oval cells with eosinophilic cytoplasms were surrounded by
abundant myxoid matrix, which was identified in a macroscopi-
cally grayish white component at the tumor wall. In addition,
plexiform and reticular capillary vasculature and lipoblasts were
absent, thus excluding myxoid liposarcoma. Moreover, atypical
pleomorphic spindle cells or pseudolipoblasts that arePlease cite this article in press as: Omori T, et al., A rare manifestatio
hematoma, Journal of Orthopaedic Science (2016), http://dx.doi.org/10.10characteristic of myxofibrosarcoma were absent. Most importantly,
the diagnosis of EMC was confirmed by the presence of the
EWSR1eNR4A3 fusion gene transcripts in RT-PCR and direct
sequencing analyses. Cytogenic studies have confirmed the unique
and characteristic chromosomal translocations in EMCs, typically
t(9; 22)(q22; q12.2) and in a other studies, in between t(9; 17)(q22;n of extraskeletal myxoid chondrosarcoma with a huge expanding
16/j.jos.2016.12.011
Fig. 5. Histopathology of the resected specimens. (A) Macroscopic view. (B and C) Hematoxylin and eosin stained areas shown by arrows in (A), 20 (B) and 40 (C) magnification.
Microscopic evaluation revealed proliferation of spindle-shaped cells and oval cells with eosinophilic cytoplasm at the wall of the tumor (C).
Fig. 6. Direct sequencing of EWSR1-NR4A3 gene using samples from the resected tumor; gene fusion was confirmed between exon 12 of EWSR1 and exon 3 of NR4A3.
T. Omori et al. / Journal of Orthopaedic Science xxx (2016) 1e54q11) and t(9; 15)(q22; q11) [12,13]. Moreover, fusion of EWSR1 and
NR4A3 genes is coincident in 85% of all EMC cases. Recently, Hisaoka
et al. reported one case with expression of both NR4A3 and SIX3 but
no NR4A3 fusion [24]. NR4A3 is an orphan nuclear receptor that
acts as a transcription factor after binding its putative coactivator
SIX3. Because the NR4A3 fusion protein has been implicated in
oncogenesis of EMC, a small fraction of EMC lacks detectable
rearrangements of the NR4A3 gene or 9q22. Similarly, SIX3
expression is specifically confined to the developing eye and fetal
forebrain, although the expression of NR4A3 is largely ubiquitous.Please cite this article in press as: Omori T, et al., A rare manifestatio
hematoma, Journal of Orthopaedic Science (2016), http://dx.doi.org/10.10Hence, these reports suggest that aberrant coexpression of NR4A3
and SIX3 is a potential alternative mechanism for the development
of EMC. The present RT-PCR analyses showed the presence of the
typical EMC fusion gene EWSR1eNR4A3 in the tumor, and
confirmed our diagnosis of EMC with a huge expanding hematoma.
Early and accurate diagnosis followed by definitive surgery is
important for the cure of EMC. Drilon et al. have reported the poor
response rate of EMC to chemotherapy and emphasize on aggres-
sive control of localized disease as the primary approach for
treatment [8]. Radiotherapy seems to be beneficial in an adjuvantn of extraskeletal myxoid chondrosarcoma with a huge expanding
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T. Omori et al. / Journal of Orthopaedic Science xxx (2016) 1e5 5setting and also for palliation of metastatic disease [25]. In our case,
we performed initial surgery with R0 resection. Although adjuvant
radiotherapy after resection of primary EMC may have been
beneficial, our patient preferred instead regular follow-ups. During
this three-year follow up period, we did not detect any distant
metastases or local recurrence. Ogura et al. have reported that
while clinical behavior of EMC is somewhat indolent, the disease
has a high propensity for local recurrence and metastases over
longer periods of 5 years [25]. Therefore, patients should be
carefully monitored over a prolonged period.
In conclusion, we reported a rare case of EMC accompanied a
large hematoma located on medial thigh of a 75-year-old woman,
mimicking chronic expanding hematoma. The molecular detection
of the EWSR1eNR4A3 fusion gene was useful in confirming our
diagnosis. We also propose that EMC should be included as one of
the differential diagnoses when a large and expanding hematoma is
detected in a soft tissue.
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